之江生物: 之江生物：2025年半年度报告摘要

Core Viewpoint - Shanghai Zhijiang Biotechnology Co., Ltd. reported significant declines in revenue and profit for the first half of 2025, indicating potential challenges in its business operations [1][2]. Company Overview - The company is listed on the Shanghai Stock Exchange with the stock code 688317 and is categorized under A-shares [1]. - As of the end of the reporting period, the total assets amounted to approximately CNY 3.78 billion, a decrease of 0.30% compared to the previous year [1]. Financial Performance - The operating revenue for the reporting period was approximately CNY 59.68 million, reflecting a decline of 36.91% year-on-year [1]. - The total profit for the period was a loss of approximately CNY 7.60 million, a significant decrease of 125.94% compared to the previous year [1]. - The net profit attributable to shareholders was approximately CNY -9.85 million, down 137.88% from the same period last year [1]. - The net profit after deducting non-recurring gains and losses was approximately CNY -13.25 million, a decline of 156.27% year-on-year [1]. Cash Flow and Earnings - The net cash flow from operating activities was approximately CNY 25.82 million, down 33.62% compared to the previous year [2]. - The basic and diluted earnings per share were both CNY -0.05, representing a decrease of 135.71% from the previous year [2]. Shareholder Information - As of the reporting period, the total number of shareholders was 15,646 [2]. - The largest shareholder, Shanghai Zhijiang Pharmaceutical Co., Ltd., held 33.81% of the shares [3].